Ajanta Pharma Limited
Our verdict
Quality (88/100) does the heavy lifting; valuation (34/100) is the drag.
Our fair value
Overvalued by 14%Buy-below (20% margin of safety): ₹2,241.42
Ajanta Pharma Limited earns a Hold from TickerMagic, with a blended score of 59/100. At ₹3,270.3 it trades above our blended DCF and relative-multiples fair value of ₹2,801.77, about 14% downside to that estimate — we read it as overvalued by 14%. On 38.5x trailing earnings it sits roughly in line with the Healthcare median of about 37.4x. The price is about 12% below its 52-week high of ₹3,718.2 and 33% above the low of ₹2,463.14. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. The average analyst target of ₹3,303.29 implies about 1% upside across 14 analysts. It clears 9 of 13 investability checks, with durability 88, valuation 42 and momentum 42 on our 0–100 scales.
Analysis by Ankit Sharma · TickerMagic's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹2,241.42.
Analyst views
1-year price
EOD · 2026-11-2052-week range
-12.05% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold59Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 25.4%
- Pass: Low debt (D/E < 0.5): 0.06x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 22%
- Pass: Earnings growing: 19%
- Pass: Net margin ≥ 10%: 19.4%
- Pass: Current ratio > 1.5: 2.64
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 17.33
- Fail: Piotroski ≥ 7: 4/9
Quarterly results
Annual financials
Shareholding
- Promoter63.4%
- Institutions21.7%
- Public & other14.9%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Strong return on equity (25.4%).
- Lightly leveraged balance sheet.
- Healthy profit margin (19.4%).
- Financially solid — Altman Z 17.33.
Opportunities
- Earnings growing (19% YoY).
- Revenue growing (22% YoY).
About Ajanta Pharma Limited
Ajanta Pharma and its subsidiaries develop, manufacture, and market specialty pharmaceutical formulations across multiple dosage forms including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company produces chronic and acute therapies as branded generic products, serving therapeutic areas in cardiology, dermatology, ophthalmology, and pain management.
Ajanta Pharma Limited — frequently asked questions
Is Ajanta Pharma Limited a buy, hold or sell?
TickerMagic currently rates Ajanta Pharma Limited (AJANTPHARM) a Hold, based on a blended score of 59/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Ajanta Pharma Limited's fair value?
Our blended DCF and relative-valuation model estimates Ajanta Pharma Limited's fair value at about ₹2,801.77, versus a current price of ₹3,270.3 — roughly 14% downside. On that basis the stock looks overvalued by 14%.
Is Ajanta Pharma Limited financially healthy?
Ajanta Pharma Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.
How has Ajanta Pharma Limited's share price performed?
Ajanta Pharma Limited is down 12% over three months, and last traded at ₹3,270.3. Past performance doesn't predict future returns.
More in Healthcare
Our verdict, fair value, financial-health and checklist are TickerMagic's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.